Page last updated: 2024-11-07

spironolactone and Kidney Diseases

spironolactone has been researched along with Kidney Diseases in 142 studies

Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.

Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.

Research Excerpts

ExcerptRelevanceReference
"Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone is associated with lower risk of heart failure hospitalization (HFH) but increased risk of worsening renal function (WRF)."9.41Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. ( Beldhuis, IE; Bristow, M; Claggett, B; Damman, K; Desai, AS; Fang, JC; Fleg, JL; Lewis, EF; McKinlay, S; Myhre, PL; O'Meara, E; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Vardeny, O; Voors, AA, 2021)
"Spironolactone reduced BP and urinary albumin, improve fibrosis and inflammation, whereas slightly increases the glycosylated haemoglobin and serum creatinine in patients with hypertension and diabetes."9.12A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes. ( Abudoyreyimu, R; Heizati, M; Li, N; Lin, M; Nurula, M; Wang, L; Wang, Z; Wu, Z; Yang, Z, 2021)
"Treatment with spironolactone (SPL) is beneficial in patients with severe congestive heart failure (CHF)."7.72How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? ( Atar, D; Galatius, S; Gustafsson, F; Hildebrandt, PR; Svensson, M, 2004)
"Six adult patients (4 females and 2 males, age range 26-57 years) with Gitelman's syndrome (GS) were treated with spironolactone 200-300 mg/day (n = 5) and/or amiloride 10-30 mg/day (n = 3) for 1-18 months."7.69Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ( Colussi, G; De Ferrari, ME; Macaluso, M; Minetti, L; Rombolà, G, 1994)
"Aldosterone plays a central role in the regulation of sodium and potassium homoeostasis by binding to the mineralocorticoid receptor and contributes to kidney and cardiovascular damage."5.43Interleukin-18 deficiency protects against renal interstitial fibrosis in aldosterone/salt-treated mice. ( Enomoto, D; Higaki, J; Kukida, M; Miyoshi, K; Nagao, T; Okamura, H; Okura, T; Pei, Z; Tanino, A, 2016)
"Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone is associated with lower risk of heart failure hospitalization (HFH) but increased risk of worsening renal function (WRF)."5.41Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. ( Beldhuis, IE; Bristow, M; Claggett, B; Damman, K; Desai, AS; Fang, JC; Fleg, JL; Lewis, EF; McKinlay, S; Myhre, PL; O'Meara, E; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Vardeny, O; Voors, AA, 2021)
" Treatment with spironolactone did not affect the biomarker of fibrosis Gal-3 in AF patients."5.41Galectin-3 in patients with atrial fibrillation and restored sinus rhythm. ( Angelov, A; Bocheva, Y; Chervenkov, T; Kisheva, A; Yotov, Y, 2021)
"Spironolactone treatment markedly suppressed osteopontin expression."5.35Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. ( Hayashida, H; Hirakata, H; Iida, M; Ikeda, H; Masutani, K; Toyonaga, J; Tsuruya, K, 2009)
"We performed this study to assess whether low dose spironolactone could be administered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardiovascular function and reduce hospitalization without inducing hyperkalemia."5.14Spironolactone in chronic hemodialysis patients improves cardiac function. ( Eshaghian, A; Garakyaraghi, M; Ghassami, M; Mortazavi, M; Pourmoghadas, A; Seirafian, S; Shahidi, S; Taheri, S, 2009)
"Spironolactone reduced BP and urinary albumin, improve fibrosis and inflammation, whereas slightly increases the glycosylated haemoglobin and serum creatinine in patients with hypertension and diabetes."5.12A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes. ( Abudoyreyimu, R; Heizati, M; Li, N; Lin, M; Nurula, M; Wang, L; Wang, Z; Wu, Z; Yang, Z, 2021)
"This study shows that spironolactone may effectively reduce proteinuria in patients with CKD."5.11Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. ( Bianchi, S; Bigazzi, R; Campese, VM, 2005)
"To compare the efficacy of three commonly used diuretic regimens in the treatment of ascites, we randomized 90 patients to three treatment groups: Sequential Spironolactone (spironolactone followed by furosemide if necessary), Combination (spironolactone and furosemide in combination), and Furosemide (furosemide given alone)."5.05Diuresis in the ascitic patient: a randomized controlled trial of three regimens. ( Fogel, MR; Gregory, PB; Knauer, CM; Miller, RG; Neal, EA; Sawhney, VK, 1981)
"Eplerenone, an aldosterone receptor antagonist from Searle is being developed as a potential treatment for renal disease, congestive heart failure and hypertension."4.81Eplerenone (GD Searle & Co). ( Krum, H; Martin, J, 2001)
"Eplerenone is a selective aldosterone blocker that effectively lowers BP in both white and black patients with hypertension and provides meaningful further antihypertensive efficacy when added to patients whose hypertension is inadequately controlled by angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers."4.81Clinical implications of aldosterone blockade. ( Weber, MA, 2002)
"Among patients with DKD and hypertension, the short-term use of MRAs, either spironolactone or eplerenone, in combination with ACEI/ARBs, was not associated with lower risk of cardiovascular or kidney outcomes compared with ACEI/ARB monotherapy."4.02Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease. ( An, J; Niu, F; Sim, JJ, 2021)
" We investigated whether spironolactone, an aldosterone receptor blocker, attenuated isoprenaline (Iso)-induced heart failure in rats and also studied the mechanism for the same."3.83Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats. ( Chen, S; Guo, Z; Liu, J; Xi, D; Zhao, J; Zhou, H, 2016)
"We prospectively studied the effects of adding spironolactone (25 mg/day) to 87 patients who maintained proteinuria higher than 1 g/day in spite of renin-angiotensin system blockade."3.79Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. ( Egido, J; Gutiérrez, E; Gutiérrez-Solís, E; Huerta, A; Millet, VG; Morales, E; Praga, M; Rojas-Rivera, J, 2013)
" Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection."3.76Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. ( Arhancet, GB; Blinn, JR; Chen, X; Collins, JT; Dietz, JD; Garland, DJ; Heron, MI; Hockerman, SL; Homer, BL; Hu, X; Huang, HC; Long, SA; Mahoney, MW; McGee, KF; Meyers, MJ; Payne, MA; Reitz, DB; Rico, JR; Wendling, JM; Yang, S, 2010)
"Treatment with spironolactone (SPL) is beneficial in patients with severe congestive heart failure (CHF)."3.72How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? ( Atar, D; Galatius, S; Gustafsson, F; Hildebrandt, PR; Svensson, M, 2004)
" The lack of therapeutic response to spironolactone, with a good response to amiloride and recurrence of hypertension and metabolic alkalosis after amiloride cessation that was subsequently treated with amiloride, established the diagnosis of Liddle syndrome."3.71Liddle syndrome in a newborn infant. ( Assadi, FK; Kimura, RE; Patel, S; Subramanian, U, 2002)
"Six adult patients (4 females and 2 males, age range 26-57 years) with Gitelman's syndrome (GS) were treated with spironolactone 200-300 mg/day (n = 5) and/or amiloride 10-30 mg/day (n = 3) for 1-18 months."3.69Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ( Colussi, G; De Ferrari, ME; Macaluso, M; Minetti, L; Rombolà, G, 1994)
"The influence of renal impairment on the pharmacokinetics of eplerenone following single and multiple dosing was evaluated."2.71Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. ( Ravis, WR; Reid, S; Sica, DA; Tolbert, DS, 2005)
"Aldosterone has been overlooked as a mediator of RAAS escape and a key factor in target-organ injury despite the use of available RAAS blockers."2.42RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. ( Lakkis, J; Lu, WX; Weir, MR, 2003)
"Treatment with losartan or spironolactone alone significantly reduced various CKD-associated features."1.56Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats. ( Aggarwal, D; Singh, G, 2020)
"Aldosterone plays a central role in the regulation of sodium and potassium homoeostasis by binding to the mineralocorticoid receptor and contributes to kidney and cardiovascular damage."1.43Interleukin-18 deficiency protects against renal interstitial fibrosis in aldosterone/salt-treated mice. ( Enomoto, D; Higaki, J; Kukida, M; Miyoshi, K; Nagao, T; Okamura, H; Okura, T; Pei, Z; Tanino, A, 2016)
"Finerenone reduced cardiac hypertrophy, plasma prohormone of brain natriuretic peptide, and proteinuria more efficiently than eplerenone when comparing equinatriuretic doses."1.40Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. ( Albrecht-Küpper, B; Bärfacker, L; Delbeck, M; Eitner, F; Hartmann, E; Kolkhof, P; Kretschmer, A; Schäfer, S; Steinke, W, 2014)
"Spironolactone treatment prevented Th17 cell activation and increased numbers of forkhead box P3-positive cells relative to DOCA-salt rats."1.40Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. ( Alzamora, R; Amador, CA; Barrientos, V; Carrasco, L; Figueroa, F; González, M; Herrada, AA; Kalergis, AM; Michea, L; Peña, J; Valdés, S, 2014)
"Hypertension is a major risk factor for the development and progression of chronic kidney disease (CKD)."1.38Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. ( Acelajado, MC; Calhoun, DA; Cartmill, FR; Cofield, SS; Dell'Italia, LJ; Dudenbostel, T; Oparil, S; Pisoni, R, 2012)
"Patients with aldosteronism had relative estimated hyperfiltration than patients with EH."1.37Kidney impairment in primary aldosteronism. ( Chang, HW; Cheng, BW; Chiang, CK; Chiu, JS; Chu, TS; Chueh, SC; Ho, YL; Hu, FC; Huang, KH; Kuo, CC; Lin, CY; Lin, JW; Lin, LY; Lin, SL; Lin, YH; Liu, KL; Tsai, CT; Wang, SM; Wu, KD; Wu, VC; Yang, SY; Yen, RF, 2011)
"Spironolactone treatment prevents renal damage induced by ischemia-reperfusion (I/R), suggesting that renoprotection conferred by spironolactone is mediated by mineralocorticoid receptor (MR) blockade."1.35Adrenalectomy prevents renal ischemia-reperfusion injury. ( Bobadilla, NA; Cruz, C; Gamba, G; Ramírez, V; Trujillo, J; Uribe, N; Valdes, R, 2009)
"Spironolactone treatment markedly suppressed osteopontin expression."1.35Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. ( Hayashida, H; Hirakata, H; Iida, M; Ikeda, H; Masutani, K; Toyonaga, J; Tsuruya, K, 2009)
"Patients with primary aldosteronism were compared with 100 patients with essential hypertension, matched for severity and duration of hypertension."1.33Long-term renal outcomes in patients with primary aldosteronism. ( Baroselli, S; Catena, C; Colussi, GL; Lapenna, R; Nadalini, E; Novello, M; Sechi, LA, 2006)
"Aldosterone treatment of cells resulted in significant up-regulation of several genes within 1 hour, with sgk, p21/waf1, gadd45, and gadd153 being the most significant ones."1.32Early aldosterone up-regulated genes: new pathways for renal disease? ( Christ, M; Falkenstein, E; Feuring, M; Hafner, M; Kellner, M; Lösel, R; Peiter, A; Wehling, M, 2003)
"Spironolactone treatment decreased PAI-1 immunoreactivity and reduced in a dose-dependent fashion cardiac and renal damage."1.32Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. ( Adler, GK; Jonasson, L; Martinez-Vasquez, D; Mukasa, K; Oestreicher, EM; Roubsanthisuk, W; Stone, JR, 2003)

Research

Studies (142)

TimeframeStudies, this research(%)All Research%
pre-199055 (38.73)18.7374
1990's3 (2.11)18.2507
2000's51 (35.92)29.6817
2010's26 (18.31)24.3611
2020's7 (4.93)2.80

Authors

AuthorsStudies
Meyers, MJ1
Arhancet, GB1
Hockerman, SL1
Chen, X1
Long, SA1
Mahoney, MW1
Rico, JR1
Garland, DJ1
Blinn, JR1
Collins, JT1
Yang, S1
Huang, HC1
McGee, KF1
Wendling, JM1
Dietz, JD1
Payne, MA1
Homer, BL1
Heron, MI1
Reitz, DB1
Hu, X1
An, J1
Niu, F1
Sim, JJ1
Choy, M1
Zhen, Z1
Dong, B1
Chen, C1
Dong, Y1
Liu, C1
Liang, W1
Xue, R1
Williams, GH1
Aggarwal, D1
Singh, G1
Leader, CJ1
Kelly, DJ1
Sammut, IA1
Wilkins, GT1
Walker, RJ1
Beldhuis, IE1
Myhre, PL1
Bristow, M1
Claggett, B1
Damman, K1
Fang, JC1
Fleg, JL1
McKinlay, S1
Lewis, EF1
O'Meara, E1
Pitt, B2
Shah, SJ1
Vardeny, O1
Voors, AA1
Pfeffer, MA1
Solomon, SD1
Desai, AS1
Lin, M1
Heizati, M1
Wang, L1
Nurula, M1
Yang, Z1
Wang, Z3
Abudoyreyimu, R1
Wu, Z1
Li, N1
Kisheva, A1
Yotov, Y1
Chervenkov, T1
Angelov, A1
Bocheva, Y1
Maiolino, G1
Calò, LA1
Amador, CA1
Barrientos, V1
Peña, J1
Herrada, AA1
González, M1
Valdés, S1
Carrasco, L1
Alzamora, R1
Figueroa, F1
Kalergis, AM1
Michea, L1
Kolkhof, P1
Delbeck, M1
Kretschmer, A1
Steinke, W1
Hartmann, E1
Bärfacker, L1
Eitner, F1
Albrecht-Küpper, B1
Schäfer, S1
Sun, QL1
Li, M1
Rui, HL1
Chen, YP1
Stewart Coats, AJ1
Shewan, L1
Martín-Fernández, B2
Rubio-Navarro, A1
Cortegano, I1
Ballesteros, S1
Alía, M1
Cannata-Ortiz, P1
Olivares-Álvaro, E1
Egido, J2
de Andrés, B1
Gaspar, ML1
de Las Heras, N2
Lahera, V2
Moreno, JA1
Zhou, H1
Xi, D1
Liu, J2
Zhao, J1
Chen, S2
Guo, Z1
Tanino, A1
Okura, T1
Nagao, T1
Kukida, M1
Pei, Z1
Enomoto, D1
Miyoshi, K1
Okamura, H1
Higaki, J1
Renke, M2
Tylicki, L2
Knap, N1
Rutkowski, P2
Neuwelt, A1
Larczynski, W2
Wozniak, M1
Rutkowski, B2
Ikeda, H1
Tsuruya, K1
Toyonaga, J1
Masutani, K1
Hayashida, H1
Hirakata, H1
Iida, M1
Kiyomoto, H2
Rafiq, K2
Mostofa, M1
Nishiyama, A4
Brem, AS2
Lea, WB1
Kwak, ES1
Luther, JM2
Fowler, SM1
Ma, J1
Fogo, AB2
Brown, NJ2
Preston, RA1
Afshartous, D1
Garg, D1
Medrano, S1
Alonso, AB1
Rodriguez, R1
Taheri, S1
Mortazavi, M1
Shahidi, S1
Pourmoghadas, A1
Garakyaraghi, M1
Seirafian, S1
Eshaghian, A1
Ghassami, M1
van den Hoven, MJ1
Waanders, F1
Rops, AL1
Kramer, AB1
van Goor, H1
Berden, JH1
Navis, G1
van der Vlag, J1
Becker, GJ1
Hewitson, TD1
Chrysostomou, A2
Du, J1
Fan, YY1
Hitomi, H2
Kimura, S1
Kong, CZ1
Noma, T1
Kohno, M1
Nakano, D2
Kandula, P1
Shah, R1
Ramírez, V3
Trujillo, J2
Valdes, R1
Uribe, N4
Cruz, C3
Gamba, G4
Bobadilla, NA4
Nemeth, Z1
Kokeny, G1
Godo, M1
Mózes, M1
Rosivall, L1
Gross, ML1
Ritz, E1
Hamar, P1
Arias-Loza, PA1
Muehlfelder, M1
Elmore, SA1
Maronpot, R1
Hu, K1
Blode, H1
Hegele-Hartung, C1
Fritzemeier, KH1
Ertl, G1
Pelzer, T1
Lopes, R1
Lourenco, P1
Mascarenhas, J1
Azevedo, A1
Bettencourt, P1
Mizuguchi, Y1
Ichihara, A1
Seki, Y1
Sakoda, M1
Kurauchi-Mito, A1
Narita, T1
Kinouchi, K1
Bokuda, K1
Itoh, H1
Bianchi, S2
Bigazzi, R2
Campese, VM2
Ando, K1
Ohtsu, H1
Arakawa, Y1
Kubota, K1
Yamaguchi, T1
Nagase, M3
Yamada, A1
Fujita, T4
Funder, JW1
Edwards, NC1
Ferro, CJ1
Kirkwood, H1
Chue, CD1
Young, AA1
Stewart, PM1
Steeds, RP1
Townend, JN1
Abolghasmi, R1
Taziki, O1
Wu, VC1
Yang, SY1
Lin, JW1
Cheng, BW1
Kuo, CC1
Tsai, CT1
Chu, TS1
Huang, KH1
Wang, SM1
Lin, YH1
Chiang, CK1
Chang, HW1
Lin, CY1
Lin, LY1
Chiu, JS1
Hu, FC1
Chueh, SC1
Ho, YL1
Liu, KL1
Lin, SL1
Yen, RF1
Wu, KD1
Miana, M1
Rodriguez, C1
Sanz-Rosa, D1
Mezzano, S1
Martinez-Gonzalez, J1
Cachofeiro, V1
Fang, Z1
Zhang, C1
He, F1
Sun, X1
Zhu, Z1
Meng, X1
Pisoni, R1
Acelajado, MC1
Cartmill, FR1
Dudenbostel, T1
Dell'Italia, LJ1
Cofield, SS1
Oparil, S1
Calhoun, DA1
Ma, TK1
Szeto, CC1
Luo, P1
Cohen, SE1
Kim, HS1
Morales, E1
Millet, VG1
Rojas-Rivera, J1
Huerta, A1
Gutiérrez, E1
Gutiérrez-Solís, E1
Praga, M1
Assadi, FK1
Kimura, RE1
Subramanian, U1
Patel, S1
Obialo, CI1
Ofili, EO1
Mirza, T1
Weber, MA1
Feria, I1
Pichardo, I1
Juárez, P1
González, MA1
García-Torres, R1
López-Casillas, F1
McMahon, EG1
Lakkis, J1
Lu, WX1
Weir, MR1
Kellner, M1
Peiter, A1
Hafner, M1
Feuring, M1
Christ, M1
Wehling, M1
Falkenstein, E1
Lösel, R1
NADASDI, M1
MANNING, RT1
BEHRLE, FC1
SJOBERG, WE1
KREISLE, JE1
BUGNON, C1
MOREAU, N1
LENYS, R1
CATTANEO, G1
DE LUCA, S1
THAYER, JM1
HEALY, FA1
DUNLOP, D1
BAGROS, P1
METCALF, MG1
PAVER, WK1
PAULINE, GJ1
MAHER, JF1
SCHREINER, GE1
SLATON, PE1
BIGLIERI, EG1
Oestreicher, EM1
Martinez-Vasquez, D1
Stone, JR1
Jonasson, L1
Roubsanthisuk, W1
Mukasa, K1
Adler, GK1
Svensson, M3
Gustafsson, F3
Galatius, S3
Hildebrandt, PR3
Atar, D3
Ali, BH1
Al-Qarawi, AA1
Mahmoud, OM1
Hashad, M1
Nitta, K1
Uchida, K1
Nihei, H1
Newsome, BB1
Warnock, DG1
Lenz, T1
Cordaillat, M1
Rugale, C1
Casellas, D1
Mimran, A1
Jover, B1
Freedman, DB1
Housley, D1
Ravis, WR1
Reid, S1
Sica, DA1
Tolbert, DS1
Kitamura, K1
Tomita, K1
Abe, Y1
Suzuki, A1
Yoshida, M1
Miura, Y1
Oiso, Y1
Sechi, LA1
Novello, M1
Lapenna, R1
Baroselli, S1
Nadalini, E1
Colussi, GL1
Catena, C1
Pérez-Rojas, J1
Blanco, JA1
Vaidya, VS1
Bonventre, JV1
Tojo, A1
Onozato, ML1
Asaba, K1
Mejía-Vilet, JM1
Matsui, H1
Shibata, S1
Gotoda, T1
Furumatsu, Y1
Nagasawa, Y1
Tomida, K1
Mikami, S1
Kaneko, T1
Okada, N1
Tsubakihara, Y1
Imai, E1
Shoji, T1
Aleksandrowicz, E1
Lysiak-Szydlowska, W1
Maebashi, M1
Yoshinaga, K1
Bufalari, A1
Meloni, G1
Siegers, CP1
Klaassen, CD1
Morgan, T1
Carney, S1
Myers, J1
Lewy, JE1
Fogel, MR1
Sawhney, VK1
Neal, EA1
Miller, RG1
Knauer, CM1
Gregory, PB1
Holzgreve, H1
Colussi, G1
Rombolà, G1
De Ferrari, ME1
Macaluso, M1
Minetti, L1
Greene, EL1
Kren, S1
Hostetter, TH1
Delyani, JA1
Epstein, M1
Becker, G1
Martin, J1
Krum, H1
Ahmida, MH1
Abdel-Gayoum, AA1
El-Fakhri, MM1
Epstein, FH1
Wilkinson, SP1
Wheeler, PG1
Bernardi, M1
Smith, IK1
Williams, R1
Susic, D1
Sparks, JC1
Vaz, AJ1
Takahashi, H1
Shibuya, Y1
Hayashida, Y1
Neale, TJ1
Lynn, KL1
Bailey, RR1
Rowe, WS1
Birkenhäger, WH1
Wester, A1
Iacona, A1
Rossetti, A1
Filingeri, V1
Orsini, D1
Cesarini, A1
Cervelli, V1
Adorno, D1
Casciani, CU1
McGeown, MG1
Morris, RG1
Frewin, DB1
Taylor, WB1
Glistak, ML1
Lehmann, DR1
Hänze, S1
Pierach, CA1
Stark, G1
Beilin, LJ1
Schiffman, N1
Crane, M1
Nelson, DH1
Brackett, NC2
Koppel, M1
Randall, RE1
Nixon, WP1
Sutherland, LE1
Hartroft, P1
Balis, JU1
Bailey, JD1
Lynch, MJ1
Desmit, EM1
Cost, WS1
Brown, JJ1
Fraser, R1
Lever, AF1
Robertson, JI1
Arant, BS1
Young, RB1
Still, WJ1
Ramanathan, K1
Gantt, C1
Grossman, A1
Modlinger, RS1
Nicolis, GL1
Krakoff, LR1
Gabrilove, JL1
Nakada, T1
Momose, G1
Yoshida, T1
Tateno, Y1
Shigematsu, H1
Selye, H1
Mantero, F1
Armanini, D1
Urbani, S1
Lagrue, G1
Fournier, A1
Jones, J1
Mills, IH1
Schmidt, P1
Kopsa, H1
Kronenberg, KH1
Meyer, D1
Zazgornik, J1
Kotzaurek, R1
Neumann, E1
Olbing, H1
Greifer, I1
Bennett, BP1
Bernstein, J1
Spitzer, A1
Dehart, HS1
Bath, NM1
Glenn, JF1
Gunnells, JC1
Cannon, PJ1
Leeming, JM1
Sommers, SC1
Winters, RW1
Laragh, JH1
Gekle, D1
Wernze, H1
Langer, KH1
Fanconi, A1
Schachenmann, G1
Nüssli, R1
Prader, A1
Levitt, JI1
Buckalew, VM1
Gall, G1
Vaitukaitis, J1
Haddow, JE1
Klein, R1
Stefan, H1
Helge, H1
Merker, HJ1
Bachmann, D1
Herman, E1
Rado, J1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981]Phase 4154 participants (Actual)Interventional2014-06-30Active, not recruiting
A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798]Phase 2/Phase 344 participants (Actual)Interventional2014-05-31Terminated (stopped due to Futility)
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055]Phase 475 participants (Anticipated)Interventional2023-08-25Recruiting
Genetic Predisposition of Chronic Nephrotoxicity From Calcineurin Inhibitors in Liver Transplant Recipients, Potential Correlation With Urinary Biomarkers[NCT00857844]207 participants (Actual)Observational2007-07-31Completed
Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658]Phase 390 participants (Anticipated)Interventional2017-08-01Not yet recruiting
Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720]Phase 2120 participants (Actual)Interventional2005-04-30Completed
A Double-Blind, Placebo-Controlled Study on the Effect of Spironolactone, in Patients With Persistent Proteinuria on Long-Term Angiotensin Converting Enzyme Inhibitor Therapy, With or With Out an Angiotensin II Receptor Blocker[NCT00106561]Phase 2/Phase 360 participants Interventional2002-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

22 reviews available for spironolactone and Kidney Diseases

ArticleYear
A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes.
    Blood pressure, 2021, Volume: 30, Issue:3

    Topics: Blood Glucose; Blood Pressure; Diabetes Complications; Humans; Hypertension; Inflammation; Kidney; K

2021
Eplerenone's role in the management of complex cardiovascular disorders.
    International journal of cardiology, 2015, Dec-01, Volume: 200

    Topics: Cardiovascular Diseases; Eplerenone; Humans; Kidney Diseases; Mineralocorticoid Receptor Antagonists

2015
Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury.
    Journal of pharmacological sciences, 2008, Volume: 108, Issue:4

    Topics: Aldosterone; Animals; Eplerenone; Humans; Kidney; Kidney Diseases; Mitogen-Activated Protein Kinases

2008
[Chronic kidney disease and the aldosterone/mineralocorticoid receptor system].
    Nihon Jinzo Gakkai shi, 2010, Volume: 52, Issue:2

    Topics: Aldosterone; Animals; Chronic Disease; Eplerenone; Humans; Kidney Diseases; Metabolic Syndrome; Mine

2010
Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney.
    Journal of pharmacological sciences, 2011, Volume: 115, Issue:1

    Topics: Aldosterone; Animals; Blood Pressure; Electrolytes; Eplerenone; Homeostasis; Humans; Kidney; Kidney

2011
Mineralocorticoid receptor antagonist for renal protection.
    Renal failure, 2012, Volume: 34, Issue:6

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Humans; Kidn

2012
Clinical implications of aldosterone blockade.
    American heart journal, 2002, Volume: 144, Issue:5 Suppl

    Topics: Aldosterone; Antihypertensive Agents; Black People; Blood Pressure; Cardiovascular Diseases; Clinica

2002
Eplerenone, a new selective aldosterone blocker.
    Current pharmaceutical design, 2003, Volume: 9, Issue:13

    Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular System; Disease Model

2003
RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.
    Current hypertension reports, 2003, Volume: 5, Issue:5

    Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Humans; Kidney Diseases; Mineralocorticoid Recepto

2003
MANAGEMENT OF RENAL DYSFUNCTION IN CONGESTIVE HEART FAILURE.
    Biochemical clinics, 1963, Volume: 2

    Topics: Acetazolamide; Benzothiadiazines; Chlorthalidone; Diuretics; Heart Failure; Humans; Kidney Diseases;

1963
[MECHANISM OF ACTION AND CLINICAL USE OF DIURETICS].
    Recenti progressi in medicina, 1963, Volume: 35

    Topics: Bendroflumethiazide; Benzothiadiazines; Chlorothiazide; Chlorthalidone; Diuretics; Hydrochlorothiazi

1963
[Roll of aldosterone in pathogenesis of kidney disorders].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2005, Jul-10, Volume: 94, Issue:7

    Topics: Aldosterone; Animals; Body Water; Disease Models, Animal; Eplerenone; Humans; Hypertension; Kidney D

2005
Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade.
    Journal of pharmacological sciences, 2006, Volume: 100, Issue:1

    Topics: Aldosterone; Animals; Cell Proliferation; Cell Shape; Cells, Cultured; Collagen; Eplerenone; Fibrobl

2006
[The importance of the biliary excretion of drugs in the human].
    Deutsche medizinische Wochenschrift (1946), 1983, Oct-14, Volume: 108, Issue:41

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bile; Biological Transport; Cardiac Glycosides; Contra

1983
Sodium and hypertension. A review of the role of sodium in pathogenesis and the action of diuretic drugs.
    Pharmacology & therapeutics, 1980, Volume: 9, Issue:3

    Topics: Age Factors; Aldosterone; Amiloride; Benzothiadiazines; Diuretics; Furosemide; Humans; Hypertension;

1980
Diuretics in infancy.
    Contributions to nephrology, 1981, Volume: 27

    Topics: Acute Disease; Benzothiadiazines; Diet, Sodium-Restricted; Diuretics; Diuretics, Osmotic; Edema; Eth

1981
Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology.
    Kidney international, 2000, Volume: 57, Issue:4

    Topics: Aldosterone; Animals; Cardiovascular Diseases; Drug Industry; Edema; Humans; Kidney Diseases; Minera

2000
Aldosterone as a determinant of cardiovascular and renal dysfunction.
    Journal of the Royal Society of Medicine, 2001, Volume: 94, Issue:8

    Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Endothelium, Vascular; Fibrosis; Huma

2001
Eplerenone (GD Searle & Co).
    Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:4

    Topics: Animals; Antihypertensive Agents; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hyper

2001
Renin and hypertension: a review article.
    The Central African journal of medicine, 1973, Volume: 19, Issue:4

    Topics: Aldosterone; Humans; Hydrochlorothiazide; Hypertension; Juxtaglomerular Apparatus; Kidney Diseases;

1973
Primary hyperaldosteronism.
    Clinics in endocrinology and metabolism, 1974, Volume: 3, Issue:3

    Topics: Adrenal Gland Neoplasms; Aldosterone; Corticosterone; Desoxycorticosterone; Electrocardiography; Hum

1974
Juxtaglomerular cell hyperplasia and secondary hyperaldosteronism (Bartter's syndrome): a re-evaluation of the pathophysiology.
    Medicine, 1968, Volume: 47, Issue:2

    Topics: Acid-Base Equilibrium; Adolescent; Adult; Aldosterone; Child; Child, Preschool; Female; Humans; Hype

1968

Trials

14 trials available for spironolactone and Kidney Diseases

ArticleYear
Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
    Journal of the American College of Cardiology, 2021, 03-09, Volume: 77, Issue:9

    Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate;

2021
Galectin-3 in patients with atrial fibrillation and restored sinus rhythm.
    Folia medica, 2021, Jun-30, Volume: 63, Issue:3

    Topics: Aged; Atrial Fibrillation; Biomarkers; Female; Fibrosis; Galectin 3; Gout; Humans; Kidney Diseases;

2021
Spironolactone attenuates oxidative stress in patients with chronic kidney disease.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 52, Issue:5

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antioxidan

2008
Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.
    Hypertension (Dallas, Tex. : 1979), 2009, Volume: 53, Issue:5

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bloo

2009
Spironolactone in chronic hemodialysis patients improves cardiac function.
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2009, Volume: 20, Issue:3

    Topics: Aged; Chronic Disease; Diuretics; Double-Blind Method; Female; Heart Failure; Humans; Hyperkalemia;

2009
Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2010, Volume: 55, Issue:4

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Disease Progression; Dru

2010
Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effect
    Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:6

    Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh

2010
Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease.
    The American journal of cardiology, 2010, Nov-15, Volume: 106, Issue:10

    Topics: Chronic Disease; Diastole; Female; Humans; Kidney Diseases; Male; Middle Aged; Mineralocorticoid Rec

2010
Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease.
    The American journal of cardiology, 2010, Nov-15, Volume: 106, Issue:10

    Topics: Chronic Disease; Diastole; Female; Humans; Kidney Diseases; Male; Middle Aged; Mineralocorticoid Rec

2010
Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease.
    The American journal of cardiology, 2010, Nov-15, Volume: 106, Issue:10

    Topics: Chronic Disease; Diastole; Female; Humans; Kidney Diseases; Male; Middle Aged; Mineralocorticoid Rec

2010
Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease.
    The American journal of cardiology, 2010, Nov-15, Volume: 106, Issue:10

    Topics: Chronic Disease; Diastole; Female; Humans; Kidney Diseases; Male; Middle Aged; Mineralocorticoid Rec

2010
Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension.
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2011, Volume: 22, Issue:1

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Chronic Disease; Double-Blind Method; Drug Resistanc

2011
Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment.
    Journal of clinical pharmacology, 2005, Volume: 45, Issue:7

    Topics: Administration, Oral; Adult; Aged; Area Under Curve; Creatinine; Eplerenone; Female; Humans; Hyperka

2005
Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 46, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

2005
Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2008, Volume: 31, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C

2008
Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 52, Issue:3

    Topics: Acetylglucosaminidase; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme

2008
Diuresis in the ascitic patient: a randomized controlled trial of three regimens.
    Journal of clinical gastroenterology, 1981, Volume: 3 Suppl 1

    Topics: Ascites; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Female; Furosemide; Hepat

1981

Other Studies

106 other studies available for spironolactone and Kidney Diseases

ArticleYear
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
    Journal of medicinal chemistry, 2010, Aug-26, Volume: 53, Issue:16

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Cell Line, Tumor; Chlorobenzenes; Crystallography,

2010
Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
    Pharmacotherapy, 2021, Volume: 41, Issue:12

    Topics: Adolescent; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardi

2021
Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction.
    ESC heart failure, 2023, Volume: 10, Issue:2

    Topics: Erythrocyte Indices; Heart Failure; Humans; Kidney Diseases; Spironolactone; Stroke Volume

2023
Aldosterone: The Missing Cardiorenal Link.
    American journal of nephrology, 2019, Volume: 50, Issue:5

    Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Diseases; Humans; Kidney Diseases; Mine

2019
Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats.
    Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:4

    Topics: Animals; Catalase; Cytokines; Glutathione; Kidney; Kidney Diseases; Losartan; Male; Rats, Wistar; Re

2020
Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat.
    Physiological reports, 2020, Volume: 8, Issue:10

    Topics: Aldosterone; Animals; Blood Pressure; Disease Models, Animal; Fibrosis; Hypertension; Kidney Disease

2020
New insights on the renal protective effects of mineralocorticoid receptor antagonists.
    Journal of hypertension, 2019, Volume: 37, Issue:1

    Topics: Humans; Kidney; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoi

2019
Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
    Hypertension (Dallas, Tex. : 1979), 2014, Volume: 63, Issue:4

    Topics: Animals; Antibodies; Desoxycorticosterone Acetate; Disease Models, Animal; Down-Regulation; Forkhead

2014
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
    Journal of cardiovascular pharmacology, 2014, Volume: 64, Issue:1

    Topics: Animals; Autoradiography; Cardiomegaly; Disease Models, Animal; Eplerenone; Heart Failure; Kidney Di

2014
Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2015, Volume: 16, Issue:2

    Topics: Adrenalectomy; Aldosterone; Animals; Chronic Disease; Cyclosporine; Cytochrome P-450 CYP11B2; Diseas

2015
Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Aldosterone; Animals; Fibrosis; Inflammation; Kidney; Kidney Diseases; Macrophages; Male; Mineraloco

2016
Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Animals; Epithelial-Mesenchymal Transition; Heart Failure; Kidney Diseases; Rats; Spironolactone; Tr

2016
Interleukin-18 deficiency protects against renal interstitial fibrosis in aldosterone/salt-treated mice.
    Clinical science (London, England : 1979), 2016, 10-01, Volume: 130, Issue:19

    Topics: Aldosterone; Animals; Blood Pressure; Fibrosis; Humans; Interleukin-18; Kidney; Kidney Diseases; Mal

2016
Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats.
    Kidney international, 2009, Volume: 75, Issue:2

    Topics: Animals; Fibrosis; Hemodynamics; Inflammation; Kidney Diseases; Male; NG-Nitroarginine Methyl Ester;

2009
The Janus effect: two faces of aldosterone.
    Kidney international, 2009, Volume: 75, Issue:2

    Topics: Adrenal Cortex Hormones; Aldosterone; Animals; Humans; Kidney Diseases; NG-Nitroarginine Methyl Este

2009
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.
    Kidney international, 2009, Volume: 75, Issue:9

    Topics: Angiotensin II; Animals; Cytochrome P-450 CYP11B2; Enzyme Inhibitors; Fibrosis; Heart Diseases; Kidn

2009
Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:9

    Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Base Sequence; Cell

2009
Aldosterone in clinical nephrology--old hormone, new questions.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:8

    Topics: Aldosterone; Eplerenone; Humans; Hypertension; Kidney Diseases; Mineralocorticoid Receptor Antagonis

2009
Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    American journal of physiology. Renal physiology, 2009, Volume: 297, Issue:3

    Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cell Hypoxia

2009
Safety of spironolactone use in ambulatory heart failure patients.
    Clinical cardiology, 2009, Volume: 32, Issue:6

    Topics: Aged; Ambulatory Care; Biomarkers; Chronic Disease; Creatinine; Evidence-Based Medicine; Female; Hea

2009
Adrenalectomy prevents renal ischemia-reperfusion injury.
    American journal of physiology. Renal physiology, 2009, Volume: 297, Issue:4

    Topics: Adrenalectomy; Aldosterone; Animals; Kidney; Kidney Diseases; Male; Nitric Oxide; Nitric Oxide Synth

2009
Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies--the effect on podocytes.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:12

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Drug Therapy, Combination; Kidney Diseases; Male;

2009
Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease.
    Toxicologic pathology, 2009, Volume: 37, Issue:7

    Topics: Aldosterone; Androstenes; Animals; Blood Pressure; Epithelial Sodium Channels; Estradiol; Female; Hy

2009
Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD.
    Nature reviews. Cardiology, 2009, Volume: 6, Issue:11

    Topics: Aortic Diseases; Chronic Disease; Humans; Hyperkalemia; Hypertrophy, Left Ventricular; Kidney Diseas

2009
Spironolactone therapy in heart failure patients with chronic kidney disease.
    Clinical cardiology, 2009, Volume: 32, Issue:10

    Topics: Biomarkers; Chronic Disease; Creatinine; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Miner

2009
Renoprotective effects of mineralocorticoid receptor blockade in heminephrectomized (pro)renin receptor transgenic rats.
    Clinical and experimental pharmacology & physiology, 2010, Volume: 37, Issue:5-6

    Topics: Aldosterone; Animals; Eplerenone; Humans; Kidney Diseases; Mineralocorticoid Receptor Antagonists; N

2010
Eplerenone in chronic renal disease: the EVALUATE trial.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Clinical Trials as Topic; Eplerenone; Female; Human

2010
Kidney impairment in primary aldosteronism.
    Clinica chimica acta; international journal of clinical chemistry, 2011, Jul-15, Volume: 412, Issue:15-16

    Topics: Glomerular Filtration Rate; Humans; Hyperaldosteronism; Hypertension; Kidney Diseases; Logistic Mode

2011
Effect of eplerenone on hypertension-associated renal damage in rats: potential role of peroxisome proliferator activated receptor gamma (PPAR-γ).
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2011, Volume: 62, Issue:1

    Topics: Animals; Blood Pressure; Connective Tissue Growth Factor; Cytokines; Down-Regulation; Eplerenone; Ge

2011
Protective effects of eplerenone on podocyte injury in adriamycin nephropathy rats.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2011, Volume: 31, Issue:3

    Topics: Animals; Cytokines; Down-Regulation; Doxorubicin; Eplerenone; Kidney Diseases; Kidney Glomerulus; Ma

2011
Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
    Journal of human hypertension, 2012, Volume: 26, Issue:8

    Topics: Acute Kidney Injury; Aged; Alabama; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting

2012
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
    Kidney international, 2012, Volume: 82, Issue:6

    Topics: Aldosterone; Angiotensin II; Animals; Aorta; Biomarkers; Blood Pressure; Cytochrome P-450 CYP11B2; D

2012
Targeting activated mineralocorticoid receptor: Occam's razor revisited.
    Kidney international, 2012, Volume: 82, Issue:6

    Topics: Aldosterone; Angiotensin II; Animals; Heart Diseases; Kidney Diseases; Mineralocorticoid Receptor An

2012
Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013, Volume: 28, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Cohort Studies; Comorbidity; Disease Progression; Fe

2013
Liddle syndrome in a newborn infant.
    Pediatric nephrology (Berlin, Germany), 2002, Volume: 17, Issue:8

    Topics: Alkalosis; Amiloride; Blood Pressure; Diuretics; Electrolytes; Failure to Thrive; Female; Humans; Hy

2002
Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.
    The American journal of cardiology, 2002, Sep-15, Volume: 90, Issue:6

    Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Diuretics; Drug Thera

2002
Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.
    Kidney international, 2003, Volume: 63, Issue:1

    Topics: Aldosterone; Animals; Chronic Disease; Collagen Type I; Collagen Type IV; Cyclosporine; Fibronectins

2003
Early aldosterone up-regulated genes: new pathways for renal disease?
    Kidney international, 2003, Volume: 64, Issue:4

    Topics: Aldosterone; Blotting, Northern; Blotting, Western; CCAAT-Enhancer-Binding Proteins; Cells, Cultured

2003
Effect of a steroid spirolactone on the cardiovascular changes produced by renal ischemia.
    Endocrinology, 1961, Volume: 69

    Topics: Aldosterone; Cardiovascular System; Diuretics; Kidney Diseases; Mineralocorticoid Receptor Antagonis

1961
Use of spironolactone in renal edema. Effectiveness and association with hyperkalemia.
    JAMA, 1961, Jun-03, Volume: 176

    Topics: Aldosterone; Diuretics; Edema; Humans; Hyperkalemia; Kidney; Kidney Diseases; Mineralocorticoid Rece

1961
Hyperkalemia and sudden death during Spironolactone (Aldactone) therapy.
    Texas state journal of medicine, 1962, Volume: 58

    Topics: Death, Sudden; Humans; Hyperkalemia; Kidney Diseases; Liver Diseases; Spironolactone

1962
[Histological study of the adrenal glomerular zone, the epiphysis, diencephalic neurosecretion and the juxtaglomerular apparatus of white rats subjected to the effects of a thioacetylated spirolactone].
    Comptes rendus des seances de la Societe de biologie et de ses filiales, 1962, Volume: 156

    Topics: Animals; Diencephalon; Epiphyses; Juxtaglomerular Apparatus; Kidney Diseases; Kidney Glomerulus; Neu

1962
[Spirolactone and lipoprotein metabolism in nephropathy in pregnancy].
    Annali di ostetricia e ginecologia, 1962, Volume: 84

    Topics: Blood Proteins; Edema; Female; Hypertension; Hypertension, Renal; Kidney; Kidney Diseases; Lipoprote

1962
[THE TREATMENT OF EDEMA WITH SULFONAMIDE DIURETICS].
    Vie medicale (Paris, France : 1920), 1964, Volume: 45

    Topics: Acetazolamide; Acidosis; Benzothiadiazines; Chlorothiazide; Chlorthalidone; Dehydration; Diuretics;

1964
SPIRONOLACTONE AND PLASMA CORTISOL.
    British medical journal, 1964, Nov-07, Volume: 2, Issue:5418

    Topics: Blood Chemical Analysis; Humans; Hydrocortisone; Kidney Diseases; Pharmacology; Rheumatic Heart Dise

1964
HYPERTENSION AND HYPERPOTASSAEMIA WITHOUT RENAL DISEASE IN A YOUNG MALE.
    The Medical journal of Australia, 1964, Aug-22, Volume: 2

    Topics: Adolescent; Chlorides; Drug Therapy; Humans; Hyperkalemia; Hypertension; Kidney Diseases; Kidney Fun

1964
STUDIES ON ETHACRYNIC ACID IN PATIENTS WITH REFRACTORY EDEMA.
    Annals of internal medicine, 1965, Volume: 62

    Topics: Alkalosis; Blood; Chlorides; Creatine; Creatinine; Diuretics; Drug Therapy; Edema; Ethacrynic Acid;

1965
HYPERTENSION AND HYPERALDOSTERONISM OF RENAL AND ADRENAL ORIGIN.
    The American journal of medicine, 1965, Volume: 38

    Topics: Adolescent; Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenalectomy; Blood; Child; Diagnosis,

1965
Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
    Circulation, 2003, Nov-18, Volume: 108, Issue:20

    Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Coronary Artery Disease; Disease Mode

2003
Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study.
    BMJ (Clinical research ed.), 2003, Nov-15, Volume: 327, Issue:7424

    Topics: Aged; Aged, 80 and over; Diuretics; Female; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Ma

2003
Influence of spironolactone treatment on gentamicin-induced nephrotoxicity in rats.
    Basic & clinical pharmacology & toxicology, 2004, Volume: 95, Issue:1

    Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Body Weight; Creatinine; Drug Synergism; Genta

2004
How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
    Journal of cardiac failure, 2004, Volume: 10, Issue:4

    Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Creatinine; Denmark;

2004
Spironolactone and angiotensin receptor blocker in nondiabetic renal diseases.
    The American journal of medicine, 2004, Sep-15, Volume: 117, Issue:6

    Topics: Angiotensin Receptor Antagonists; Diabetic Nephropathies; Female; Humans; Kidney Diseases; Male; Mid

2004
[Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure. A retrospective analysis of 125 consecutive cases].
    Ugeskrift for laeger, 2004, Sep-06, Volume: 166, Issue:37

    Topics: Aged; Aged, 80 and over; Diuretics; Female; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Ma

2004
Hyperkalemia after the publication of RALES.
    The New England journal of medicine, 2004, Dec-02, Volume: 351, Issue:23

    Topics: Creatinine; Heart Failure; Hospitalization; Humans; Hyperkalemia; Kidney Diseases; Mineralocorticoid

2004
[The 10-minute consultation. Accidental finding: hyperkalemia. Caution with analgesics and bananas].
    MMW Fortschritte der Medizin, 2005, Jan-27, Volume: 147, Issue:4

    Topics: Aged; Analgesics; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Coronary Disease; Diabetes Melli

2005
Cardiorenal abnormalities associated with high sodium intake: correction by spironolactone in rats.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2005, Volume: 289, Issue:4

    Topics: Administration, Oral; Animals; Blood Pressure; Body Weight; Cardiomegaly; Diuretics; Drug Interactio

2005
Gitelman's syndrome presenting as intolerance to statin therapy.
    Annals of clinical biochemistry, 2005, Volume: 42, Issue:Pt 3

    Topics: Adult; Amiloride; Cholesterol; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutar

2005
Gitelman's syndrome with silent thyroiditis.
    Nagoya journal of medical science, 2006, Volume: 68, Issue:1-2

    Topics: Adult; Calcium; Female; Humans; Hypokalemia; Kidney Diseases; Magnesium; Muscular Diseases; Spironol

2006
Long-term renal outcomes in patients with primary aldosteronism.
    JAMA, 2006, Jun-14, Volume: 295, Issue:22

    Topics: Adrenalectomy; Adult; Albuminuria; Female; Glomerular Filtration Rate; Humans; Hyperaldosteronism; H

2006
Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.
    American journal of physiology. Renal physiology, 2007, Volume: 292, Issue:1

    Topics: Animals; Apoptosis; Arterioles; Blood Pressure; Body Weight; Caspase 3; Cell Adhesion Molecules; Cyc

2007
Spironolactone with ACE inhibitor is effective in gross hematuria caused by nephroptosis.
    International journal of urology : official journal of the Japanese Urological Association, 2006, Volume: 13, Issue:7

    Topics: Biopsy; Diagnosis, Differential; Female; Follow-Up Studies; Hematuria; Humans; Kidney; Kidney Diseas

2006
Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone.
    American journal of physiology. Renal physiology, 2007, Volume: 293, Issue:1

    Topics: Aldosterone; Animals; Blotting, Western; Catalase; Glutathione Peroxidase; Immunohistochemistry; In

2007
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:5

    Topics: Aldosterone; Animals; Antioxidants; Cyclic N-Oxides; Disease Models, Animal; Eplerenone; Hypertensio

2007
Lasix.
    The Medical letter on drugs and therapeutics, 1967, Jan-27, Volume: 9, Issue:2

    Topics: Diuresis; Edema; Furosemide; Heart Failure; Humans; Kidney Diseases; Liver Cirrhosis; Potassium Defi

1967
Changes in plasma renin activity after administration of spironolactone.
    Japanese circulation journal, 1967, Volume: 31, Issue:3

    Topics: Adolescent; Adult; Aortic Coarctation; Blood Pressure; Cushing Syndrome; Female; Glomerulonephritis;

1967
[The behavior of uricemia during treatment with spironolactone and with other diuretics].
    Minerva medica, 1967, Nov-07, Volume: 58, Issue:89

    Topics: Acetazolamide; Adolescent; Adult; Aged; Chlorthalidone; Clopamide; Diuretics; Ethacrynic Acid; Femal

1967
[Therapy of cardiac insufficiency with diuretics].
    Fortschritte der Medizin, 1982, Aug-26, Volume: 100, Issue:31-32

    Topics: Amiloride; Benzothiadiazines; Blood Glucose; Diuretics; Drug Administration Schedule; Female; Furose

1982
Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome.
    American journal of nephrology, 1994, Volume: 14, Issue:2

    Topics: Adult; Aldosterone; Amiloride; Bartter Syndrome; Blood Gas Analysis; Blood Pressure; Creatinine; Dru

1994
Role of aldosterone in the remnant kidney model in the rat.
    The Journal of clinical investigation, 1996, Aug-15, Volume: 98, Issue:4

    Topics: Adrenal Glands; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biph

1996
Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Drug Therapy, Combination; E

2001
Effect of spironolactone on cisplatin-induced nephrotoxicity in rabbits.
    Human & experimental toxicology, 2001, Volume: 20, Issue:9

    Topics: Animals; Antineoplastic Agents; Cisplatin; Diuretics; Drug Therapy, Combination; Kidney Diseases; Ki

2001
Spironolactone and ACE inhibition in chronic renal failure.
    The New England journal of medicine, 2002, Feb-07, Volume: 346, Issue:6

    Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Drug Therapy, Combination; Humans; Hyperte

2002
Diuretic-induced renal impairment without volume depletion in cirrhosis: changes in the renin-angiotensin system and the effect of beta-adrenergic blockade.
    Postgraduate medical journal, 1979, Volume: 55, Issue:654

    Topics: Adrenergic beta-Antagonists; Adult; Creatinine; Female; Furosemide; Humans; Kidney; Kidney Diseases;

1979
Differentiation of nephrotensin from the renin angiotensin system.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1975, Volume: 148, Issue:4

    Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodies; Atropine; Biological

1975
Clinical use of spironolactone.
    American heart journal, 1979, Volume: 97, Issue:4

    Topics: Diabetes Complications; Humans; Hyperkalemia; Kidney Diseases; Spironolactone

1979
Preventive mechanism of spironolactone against mercury-induced renal damage: role of metallothionein.
    Toxicology and applied pharmacology, 1979, Volume: 47, Issue:2

    Topics: Animals; Kidney; Kidney Diseases; Male; Mercury; Mercury Poisoning; Metalloproteins; Metallothionein

1979
[Study on potassium transport in the intestine compensatory potassium excretion mechanism increasing factors of potassium secretion (author's transl)].
    Nihon Jinzo Gakkai shi, 1978, Volume: 20, Issue:6

    Topics: Aldosterone; Animals; Biological Transport; Humans; Intestinal Mucosa; Kidney Diseases; Male; Postur

1978
Spironolactone-associated aggravation of renal functional impairment.
    The New Zealand medical journal, 1976, Mar-10, Volume: 83, Issue:559

    Topics: Aged; Female; Humans; Hyperkalemia; Kidney Diseases; Middle Aged; Spironolactone

1976
Some aspects of the management of hypertension II. Special considerations.
    The Medical journal of Australia, 1975, Mar-08, Volume: 1, Issue:10

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure Determination; Diazoxide; Drug Therapy, Combina

1975
[A question of logic].
    Nederlands tijdschrift voor geneeskunde, 1976, Jun-12, Volume: 120, Issue:24

    Topics: Diazoxide; Furosemide; Humans; Hyperaldosteronism; Hypertension; Kidney Diseases; Male; Middle Aged;

1976
Reduced nephrotoxicity and hepatoxicity in cyclosporin A therapy by enalapril and spironolactone in rats.
    Drugs under experimental and clinical research, 1991, Volume: 17, Issue:10-11

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cyclosporine; Drug Therapy, Combination; Enalapril;

1991
Spironolactone and hyperkalaemia in patients with impaired renal failure.
    Lancet (London, England), 1987, Nov-21, Volume: 2, Issue:8569

    Topics: Humans; Hyperkalemia; Kidney Diseases; Spironolactone

1987
The effect of renal and hepatic impairment and of spironolactone on digoxin immunoassays.
    European journal of clinical pharmacology, 1988, Volume: 34, Issue:3

    Topics: Aged; Aged, 80 and over; Digoxin; Female; Humans; Immunoassay; Kidney Diseases; Liver Diseases; Male

1988
[Bartter syndrome. Vascular angiotensin II resistance with juxtaglomerular cellular hyperplasia and hyperaldosteronism].
    Deutsche medizinische Wochenschrift (1946), 1965, Nov-12, Volume: 90, Issue:46

    Topics: Adult; Angiotensin II; Humans; Hyperaldosteronism; Hyperplasia; Hypokalemia; Kidney Diseases; Potass

1965
Hypokalaemic alkalosis and hyperplasia of the juxtaglomerular apparatus without hypertension or oedema.
    British medical journal, 1967, Nov-11, Volume: 4, Issue:5575

    Topics: Adolescent; Alkalosis; Angiotensin II; Blood Pressure; Extracellular Space; Humans; Hyperaldosteroni

1967
Hyperplasia of the juxtaglomerular complex with secondary aldosteronism without hypertension (Bartter's syndrome).
    The American journal of medicine, 1968, Volume: 44, Issue:5

    Topics: 17-Ketosteroids; Adrenocorticotropic Hormone; Aldosterone; Ammonium Chloride; Angiotensin II; Bicarb

1968
Bartter's syndrome. A report of four cases, including three in one sibship, with comparative histologic evaluation of the juxtaglomerular apparatuses and glomeruli.
    Acta paediatrica Scandinavica. Supplement, 1970, Volume: 201

    Topics: Alkalosis; Angiotensin II; Blood Pressure; Carbon Dioxide; Cerebrospinal Fluid Proteins; Electrolyte

1970
An unusual type of hypokalaemic alkalosis with a disturbance of renin and aldosterone.
    Acta endocrinologica, 1970, Volume: 64, Issue:1

    Topics: Adolescent; Adrenal Cortex Hormones; Albumins; Aldosterone; Alkalosis; Angiotensin II; Creatinine; D

1970
Case studies of siblings with juxtaglomerular hyperplasia and secondary aldosteronism associated with severe azotemia and renal rickets--Bartter's syndrome or disease?
    Pediatrics, 1970, Volume: 46, Issue:3

    Topics: Aldosterone; Alkalosis; Angiotensin II; Bone Diseases; Child; Child, Preschool; Humans; Hyperaldoste

1970
Six year follow-up of a child with Bartter syndrome.
    American journal of diseases of children (1960), 1973, Volume: 126, Issue:2

    Topics: Aldosterone; Alkalosis; Angiotensin II; Biopsy; Blood Pressure; Child, Preschool; Diet Therapy; Fema

1973
Some observations on the pathogenesis of Bartter's syndrome.
    The New England journal of medicine, 1973, Nov-08, Volume: 289, Issue:19

    Topics: Adult; Aldosterone; Alkalosis; Angiotensin II; Blood Volume; Drug Therapy, Combination; Humans; Hype

1973
Renin-angiotensin-aldosterone system of a woman with Bartter's syndrome: Juxtaglomerular cell hyperplasia without hypertension.
    The Journal of urology, 1974, Volume: 112, Issue:3

    Topics: Adult; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Female; Humans; Hyperaldosteronism; Hyp

1974
Protection by glucocorticoids against allopurinol nephropathy.
    Acta endocrinologica, 1972, Volume: 69, Issue:2

    Topics: Allopurinol; Animals; Desoxycorticosterone; Estradiol; Ethylestrenol; Female; Kidney; Kidney Disease

1972
Antihypertensive effect of spironolactone in essential, renal and mineralocorticoid hypertension.
    Clinical science and molecular medicine. Supplement, 1973, Volume: 45 Suppl 1

    Topics: Adult; Aldosterone; Female; Humans; Hyperaldosteronism; Hypertension; Hypertension, Renal; Kidney Di

1973
[Nephrology in 1972].
    La Revue du praticien, 1972, May-21, Volume: 22, Issue:15

    Topics: Bone Resorption; Calcium; Dextrans; Female; Fluorescent Antibody Technique; Gentamicins; Glomerulone

1972
[Bartter's syndrome in adults. Case report with light- and electron-microscopic findings].
    Deutsche medizinische Wochenschrift (1946), 1973, Apr-06, Volume: 98, Issue:14

    Topics: Adult; Alkalosis; Female; Humans; Hyperaldosteronism; Hyperplasia; Hypertrophy; Hypokalemia; Hypoten

1973
Idiopathic membranous nephropathy in children.
    Kidney international, 1973, Volume: 3, Issue:6

    Topics: Adolescent; Age Factors; Aminohippuric Acids; Basement Membrane; Biopsy; Child; Child, Preschool; Cr

1973
Urologic considerations in Bartter's syndrome.
    The Journal of urology, 1974, Volume: 111, Issue:4

    Topics: Adolescent; Adult; Biopsy; Carpal Bones; Female; Foot; Humans; Hydronephrosis; Hyperaldosteronism; H

1974
[Problems in Bartter's syndrome].
    Monatsschrift fur Kinderheilkunde, 1971, Volume: 119, Issue:7

    Topics: Alkalosis; Biopsy; Child, Preschool; Female; Glomerular Filtration Rate; Humans; Hyperaldosteronism;

1971
Chronic hypokalaemia with growth retardation, normotensive hyperrenin-hyperaldosteronism ("Bartter's syndrome"), and hypercalciuria. Report of two cases with emphasis on natural history and on catch-up growth during treatment.
    Helvetica paediatrica acta, 1971, Volume: 26, Issue:2

    Topics: Alkalosis; Calcium; Child; Chronic Disease; Female; Growth Disorders; Humans; Hyperaldosteronism; Hy

1971
Spironolactone therapy and amenorrhea.
    JAMA, 1970, Mar-23, Volume: 211, Issue:12

    Topics: Adult; Amenorrhea; Female; Humans; Kidney Diseases; Menstruation Disturbances; Spironolactone

1970
Clinical usage of the newer diuretic agents.
    Journal of the Medical Association of Georgia, 1970, Volume: 59, Issue:10

    Topics: Diuretics; Ethacrynic Acid; Furosemide; Humans; Hypokalemia; Kidney Diseases; Spironolactone; Triamt

1970
Erythrocyte Na flux in a patient with Bartter's syndrome.
    The Journal of clinical endocrinology and metabolism, 1971, Volume: 32, Issue:4

    Topics: Aldosterone; Alkalosis; Ammonium Chloride; Biological Transport; Biological Transport, Active; Cell

1971
[Kidney artery stenosis, renal hypertension and secondary hyperaldosteronism in an 8-year-old boy. (Stunted growth through potassium deficiency)].
    Helvetica paediatrica acta, 1968, Volume: 23, Issue:5

    Topics: Adrenal Glands; Aldosterone; Child; Dwarfism; Humans; Hyperaldosteronism; Hypertension, Renal; Hypok

1968
Fatal hyperkalemic paralysis associated with spironalactone. Observation on a patient with severe renal disease and refractory edema.
    Archives of neurology, 1966, Volume: 15, Issue:1

    Topics: Adult; Diabetes Mellitus; Diabetic Nephropathies; Edema; Heart Failure; Humans; Hyperkalemia; Hypert

1966